MX384151B - Variantes de desintegrina y usos farmacéuticos de las mismas. - Google Patents

Variantes de desintegrina y usos farmacéuticos de las mismas.

Info

Publication number
MX384151B
MX384151B MX2017002323A MX2017002323A MX384151B MX 384151 B MX384151 B MX 384151B MX 2017002323 A MX2017002323 A MX 2017002323A MX 2017002323 A MX2017002323 A MX 2017002323A MX 384151 B MX384151 B MX 384151B
Authority
MX
Mexico
Prior art keywords
disintegrin variants
pharmaceutical uses
disintegrin
variants
integrin
Prior art date
Application number
MX2017002323A
Other languages
English (en)
Other versions
MX2017002323A (es
Inventor
Woei-Jer Chuang
Original Assignee
Univ Nat Cheng Kung
Dcb Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Cheng Kung, Dcb Usa Llc filed Critical Univ Nat Cheng Kung
Publication of MX2017002323A publication Critical patent/MX2017002323A/es
Publication of MX384151B publication Critical patent/MX384151B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención se refiere a variantes de desintegrina que se unen específicamente a uno o más de a5ß1 e integrinas av, tales como avß1, avß3, avß5, avß6 y avß8, pero con una reducción en la actividad de unión a aIIbß3; también se describen los usos de las variantes de desintegrina para el tratamiento o prevención de una enfermedad asociada con una integrina av o una integrina a5ß1.
MX2017002323A 2014-08-22 2015-08-21 Variantes de desintegrina y usos farmacéuticos de las mismas. MX384151B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040503P 2014-08-22 2014-08-22
PCT/US2015/046322 WO2016029131A1 (en) 2014-08-22 2015-08-21 Disintegrin variants and pharmaceutical uses thereof

Publications (2)

Publication Number Publication Date
MX2017002323A MX2017002323A (es) 2017-08-02
MX384151B true MX384151B (es) 2025-03-14

Family

ID=55351297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002323A MX384151B (es) 2014-08-22 2015-08-21 Variantes de desintegrina y usos farmacéuticos de las mismas.

Country Status (12)

Country Link
US (2) US10508137B2 (es)
EP (1) EP3182988A4 (es)
JP (1) JP6886917B2 (es)
KR (1) KR102102789B1 (es)
CN (1) CN106714818B (es)
AU (1) AU2015305299B2 (es)
CA (1) CA2958906C (es)
MX (1) MX384151B (es)
RU (1) RU2685869C1 (es)
SG (1) SG11201700114WA (es)
TW (2) TWI579299B (es)
WO (1) WO2016029131A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958906C (en) * 2014-08-22 2021-05-04 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
MX382540B (es) * 2015-06-28 2025-03-13 Allgenesis Biotherapeutics Inc Proteinas de fusion para inhibir la angiogenesis
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
US11202854B2 (en) * 2017-08-09 2021-12-21 National Taiwan University Disintegrin variants and uses thereof
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380646A (en) * 1992-10-19 1995-01-10 Temple University Of The Commonwealth System Of Higher Education Thrombus detection using radiolabelled disintegrins
US7220724B2 (en) 1993-10-22 2007-05-22 University Of Southern California Contortrostatin CN and methods for its use in preventing metastasis and other conditions
US7452551B1 (en) * 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
NZ543122A (en) * 2003-03-24 2008-07-31 Sequoia Pharmaceuticals Inc An HIV fusion inhibitor peptide covalently linked to a blood protein
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8183201B2 (en) 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
EP2456454A4 (en) * 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
KR20120130752A (ko) * 2009-12-23 2012-12-03 내셔널 타이완 유니버시티 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
CA2789679A1 (en) * 2010-02-11 2011-08-18 University Of Southern California Modified adam disintegrin domain polypeptides and uses thereof
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
WO2015048354A1 (en) * 2013-09-25 2015-04-02 Markland Francis S Jr Compositions and methods for treating ovarian cancer including preventing the recurrence thereof
CA2958906C (en) * 2014-08-22 2021-05-04 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
MX382540B (es) * 2015-06-28 2025-03-13 Allgenesis Biotherapeutics Inc Proteinas de fusion para inhibir la angiogenesis

Also Published As

Publication number Publication date
TW201609793A (zh) 2016-03-16
US10870684B2 (en) 2020-12-22
KR102102789B1 (ko) 2020-04-24
AU2015305299B2 (en) 2018-11-01
EP3182988A4 (en) 2018-05-23
MX2017002323A (es) 2017-08-02
RU2017105771A (ru) 2018-09-24
TW201708250A (zh) 2017-03-01
AU2015305299A1 (en) 2017-02-09
CA2958906C (en) 2021-05-04
WO2016029131A1 (en) 2016-02-25
BR112017003334A8 (pt) 2018-02-06
EP3182988A1 (en) 2017-06-28
RU2685869C1 (ru) 2019-04-23
US20200010516A1 (en) 2020-01-09
KR20170042366A (ko) 2017-04-18
US20170267731A1 (en) 2017-09-21
SG11201700114WA (en) 2017-02-27
JP2017525394A (ja) 2017-09-07
US10508137B2 (en) 2019-12-17
RU2017105771A3 (es) 2018-09-24
CA2958906A1 (en) 2016-02-25
JP6886917B2 (ja) 2021-06-16
TWI579299B (zh) 2017-04-21
CN106714818B (zh) 2020-04-21
BR112017003334A2 (pt) 2017-11-28
CN106714818A (zh) 2017-05-24
TWI563001B (en) 2016-12-21

Similar Documents

Publication Publication Date Title
EP2859498A4 (en) RELIABLE SAFETY RANGE ACCESS TO PERIPHERAL DEVICES
HRP20190258T8 (hr) Ambalažna konstrukcija i postupci proizvodnje navedene ambalažne konstrukcije
EP2897593A4 (en) BIOABCABLE MICRO CAPSULES WITH A FILLING MATERIAL
IL235934B (en) Engineered botulinum neurotoxin
DK3151663T3 (da) Ex vivo-organplejesystem
HUE045646T2 (hu) Komplement aktivitás modulálása
PT3205720T (pt) Vetor de expressão de car e células t que expressam car
EP3009547A4 (en) FABRIC AND TEXTILE PRODUCT THEREFOR
EP2964022A4 (en) ANALGIC COMBINATION AND USE
CL2014002326A1 (es) Combinacion que comprende benzodioxanos y uno o mas agentes activos y su uso en el tratamiento de enfermedades tales como ateroesclerosis e infarto al miocardio.
EP3872134C0 (de) Polymerzusammensetzung enthaltend plla und pdla
PT2804475T (pt) Criopreservação de células, tecidos e órgãos
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
EP2928463A4 (en) LYOPHILIZED PREPARATIONS OF MELPHALAN FLUFENAMIDE
SMT201500320B (it) Liofilizzazione di agente tensioattivo polmonare liposomale sintetico
EP3579960A4 (en) ISOTHERMAL REACTOR
MX2017002323A (es) Variantes de desintegrina y usos farmaceuticos de las mismas.
DE112014001775A5 (de) Sicherheitsplombe für medizintechnischen Sterilcontainer
UY34609A (es) Motivos de interacción de transactivación en plantas y sus usos
CL2016000462A1 (es) Ensamble estructural y método de ensamble del mismo
EP2978841A4 (en) ENTEROCOCCUS FAECALIS BACTERIOPHAGES AND USES THEREOF
IL248629A0 (en) Cycloalkyl-linked diheterocycle derivatives
BR112015030129A2 (pt) ésteres sulfatados de ácido oligohidróxi carboxílico e seu uso
CL2015002642A1 (es) Anticuerpo monoclonal, inhibiendo la actividad enzimática de la lipasa endotelial vascular.
EP2808025A4 (en) PHARMACEUTICAL COMPOSITION AND QUASI MEDICAMENT COSMETICS THEREWITH